Last year, British Columbia became the first province to introduce a mandatory biosimilar switching program for non-medical reasons.
access to new drugs
New clinical trials registered with Health Canada fell by more than 52 per cent.
More regulation will likely lead to slower and more limited access to drugs.
Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.
A national formulary—essentially a list of drugs—is unlikely to match the comprehensive lists covered by private insurance plans.
Developing and testing new drugs costs a lot of money.
Profit incentivizes innovation and helps fund research and development.
Review board’s new reference countries have more limited access to new and innovative drugs.